Analytical Data
-
Gene name
Zaire ebolavirus VP30
- Application
-
Alternative Names
Transcription activator VP30
-
Species
Zaire ebolavirus
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q77DJ5
-
Expression Region
1-288aa
-
Molecular Weight
34.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Zaire ebolavirus (ZEBOV) is one of the most virulent viruses responsible for severe outbreaks of Ebola virus disease, characterized by high mortality rates. The viral protein VP30 is a key component of the ZEBOV genome and plays a critical role in viral transcription and replication. VP30 acts as a transcription factor that is essential for the synthesis of viral mRNA, making it a potential target for therapeutic interventions. Research into the structural and functional properties of VP30 has garnered attention due to its implications for vaccine and antiviral drug development. The recombinant production of VP30 allows for detailed studies of its interaction with other viral components and host factors, providing insights into the mechanisms of ZEBOV pathogenesis. Furthermore, understanding the immunogenicity of VP30 could lead to novel vaccine candidates that elicit a robust immune response. With advances in biotechnology, such as recombinant DNA techniques, scientists are now able to produce VP30 in sufficient quantities for structural analysis and to assess its potential as a vaccine target. This research not only contributes to the fundamental understanding of Zaire ebolavirus biology but also holds promise for developing effective strategies to combat one of the world’s most lethal viruses, particularly in regions facing recurrent outbreaks. The ongoing studies on VP30 are vital for enhancing preparedness against future Ebola outbreaks and could provide a framework for tackling other emerging viral threats.
